|
Name:
|
MartiniMan
-
|
Subject:
|
Most Current Reality Check
|
Date:
|
8/22/2022 11:38:10 AM
|
|
Besides being just one study that came to a similar conclusion as others and opposite conclusion as others, the authors made the following recommendation: These findings, along with additional prospective studies supporting the use of higher-dose fluvoxamine and ivermectin, provided the evidence to include all three medications (my emphasis added) as well as combination arms. So unlike the Goofy grabbing headline, the authors of this study in the "prestigous NEJM" recommended use of all three medications. And of course we know that the metadata studies as well as numerous other clinical studies have demonstrated that Ivermectin works if given in high enough doses early in the infection (within 3 days of onset of symptoms).
Having actually read the study they prescribed a 14-day dosing of the two other medications and only 3 days of Ivermectin. From the study: The groups received the trial drugs according to the following doses: immediate-release metformin administered with an increase in dose over 6 days to 1500 mg per day for 14 days, ivermectin at a dose of 390 to 470 μg per kilogram per day for 3 days (my emphasis added), and fluvoxamine at a dose of 50 mg twice daily for 14 days. Note that the dosage of metformin was increased over the course of treatment. Not so for the Ivermectin or Fluvoxamine. And the authors admit that using higher doses of Ivermectin, something recommended by the FLCC, could have changed the outcome of the study. They also limited the study to people who were overweight or obese based on their BMI.
Interestingly, when you compare the reduction in symptoms for all three drugs they are almost identical to the placebo (Figure 2 in the study). And none of them prevented hypoxia (defined as O2 levels at or below 94%). And while Metformin performed better than the other two, Ivermectin reduced the incidences of hospitalization and death (0.73).....just not as much as the metformin (0.47) but significantly better than Fluvoxamine (1.11). Note that the authors admit that the cases of hospitalization and death in all instances (placebo and the three medications) were rare (2% and 0.2%, respectively). Think about that one......98% never needed to go to the hospital and 99.8% survived. To me that is the most important aspect of this study, not the lower efficacy of Ivermectin over Metformin.
Finally, I suggest you also read the limitations of the study as they are an important factor to consider. There are many and they are fairly substantial ones. You have to read beyond the slanted headlines to get the real facts.....something Goofy never does.
|